Accuray touts ASTRO results in breast cancer therapy

Accuray is highlighting clinical results that suggest that early-stage breas...Read more on AuntMinnie.comRelated Reading: Accuray reports revenue gains for Q1 Accuray to introduce Volo Ultra at ASTRO 2021 Accuray inks collaboration with C-RAD Accuray promotes prostate cancer research at ESTRO 2021 Accuray lands Radixact install in India
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

This study aims to investigate the long-term risk of a SPM attributable to the radiation therapy in patients with the initial lung cancer.METHODS: Patients initially diagnosed with lung cancer between January 1975 and November 2011 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. SPM was defined as the occurrence of a second cancer at least five years after the diagnosis of the initial lung cancer. Age- and propensity score matching (PSM)-adjusted competing risk analyses were performed to compare the risk of SPM.RESULTS: Of 47,911 patients, 9,162 (19.1%) underwent radiotherapy for the i...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Authors: Source Type: research
“Having cancer is terrifying. It’s scary. And going to the hospital—I really felt like a number,” says Marc Hulett, who was diagnosed with prostate cancer in 2004. Hulett had surgery to remove his prostate and has been on hormone therapy for 17 years. Every three months, he gets a blood test to monitor his progress, but he no longer feels like a number. He drives from his home in Palm Springs, Calif., to Los Angeles—which can take up to six hours—to see his oncologist, Dr. David Agus, at the Ellison Institute for Transformative Medicine. As the name suggests, the Institute isn’t ju...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthscienceclimate Source Type: news
J Clin Med. 2021 Oct 17;10(20):4762. doi: 10.3390/jcm10204762.ABSTRACTThe goal of this investigation was to identify potential risk factors to predict the onset of medication-related osteonecrosis of the jaw (MRONJ). Through the identification of the multiple variables positively associated to MRONJ, we aim to write a paradigm for integrated MRONJ risk assessment built on the combined analysis of systemic and local risk factors. The characteristics of a cohort of cancer patients treated with zoledronic acid and/or denosumab were investigated; beyond the set of proven risk factors a new potential one, the intake of new mole...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Mol Biol Rep. 2021 Oct 20. doi: 10.1007/s11033-021-06752-9. Online ahead of print.ABSTRACTCancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment br...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Source Type: research
Avenda Health, a medtech company based in Santa Monica, California has developed the Focal Therapy System. It provides AI-powered prostate cancer therapy with the aim of treating only tumorous tissues, while reducing side-effects compared with conven...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Informatics Oncology Urology Source Type: blogs
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The serum and glucocorticoid inducible protein kinase (SGK) family signals downstream of phosphoinositide-3-kinase (PI3K) and is made up of three isoforms: SGK1, 2, and 3. respectively, and their activity is dependent on growth factor activation. Among these SGK families, one such potential target and a less explored enzyme is SGK3. SGK3 regulates a range of basic cellular processes, such as cell proliferation, migration and survival, thus playing an important role in cancer development. These kinase-signaling pathways present both opportunities and challenges for cancer therapy. In this paper, we reviewed the status of SG...
Source: Current Signal Transduction Therapy - Category: Molecular Biology Source Type: research
Conclusion: It is imperative to unify efforts where developing countries might invest in obtaining databases of genomic profiles of their populations, and developed countries might incorporate racial/ethnic minority populations in future clinical trials and cancer researches with the overall objective of fomenting pharmacogenomics in clinical practice and public health policies.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Bull Cancer. 2021 Mar 5:S0007-4551(21)00049-7. doi: 10.1016/j.bulcan.2020.12.007. Online ahead of print.ABSTRACTNumerous epigenetic alterations are observed in cancer cells, and dysregulation of mono-ubiquitination of histone H2B (H2Bub1) has often been linked to tumorigenesis. H2Bub1 is a dynamic post-translational histone modification associated with transcriptional elongation and DNA damage response. Histone H2B monoubiquitination occurs in the site of lysine 120, written predominantly by E3 ubiquitin ligases RNF20/RNF40 and deubiquitinated by ubiquitin specific peptidase 22 (USP22). RNF20/40 is often altered in the pri...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | India Health | Prostate Cancer | Radiology